摘要
目的研究尤瑞克林注射液对脑梗死患者血清基质金属蛋白酶9(matrix metalloproteinase-9,MMP-9)及预后的影响,探讨尤瑞克林注射液治疗脑梗死的作用机制。方法采用随机、双盲的方法,将发病48 h内入院的大面积脑梗死患者50例分为对照组和尤瑞克林组(尤瑞克林注射液0.15 PNA/d),每组25例,连续用药14 d。治疗前后检测血清MMP-9水平,应用美国国立卫生研究院脑卒中量表(NIHSS)及日常生活活动量表Barthel指数(BI)记分法对入院后当天及3个月时神经功能缺损程度进行评分。结果除尤瑞克林组1例患者用药后血压下降,无其他不良反应。对照组和尤瑞克林组治疗后14 d血清MMP-9水平明显降低,且尤瑞克林组较对照组明显降低,差异有统计学意义(P<0.01);对照组和尤瑞克林组治疗后3个月神经功能缺损程度评分较治疗前明显改善,且尤瑞克林组神经功能缺损程度评分改善明显优于对照组(P<0.01)。结论短期应用尤瑞克林注射液可以改善脑梗死患者的预后,其机制可能与降低血清MMP-9水平有关。
Objective To investigate the effects of Kallikrein on serum matrix metalloproteinase-9 （MMP-9） and prognosis in patients with cerebral infarction,and to explore the mechanism of Kallikrein in treating ischemic stroke. Methods Fifty patients with cerebral infarction（less than 48 hours from symptom onset） were divided by random, double-blind method into control group and Kallikrein group. Each group was continuously given basal treatment for 14-days, Kallikrein group was given additional Kallikrein treatment（Kallikrein 0.15 PNA iv drip per day）. The serum levels of MMP 9 were detected before and after treatment. All patients nerve function was assessed by National Institutes of Health Stroke Scale（NIHSS） and Barthel Index （BI） at admission and 3 months after admission. Results There was no side effect except decreasing blood pressure in one patient of Kallikrein group, After 14 days of treatment,obvious decrease in serum MMP-9 concen- tration was seen in both groups compared with before treatment, and Kallikrein group was more significant than control group （P ~ 0.01）. At 3 month after admission, neurological functional deficit scores in the two groups were significantly improved compared with at admission,and Kallikrein group had better results than control group （P 〈 0. 01）. Conclusion Short time use of Kallikrein can improve the prognosis of patients with cerebral infarction,the probable mechanism is related to the decreased levels of serum MMP-9.
出处
《中华老年心脑血管病杂志》
CAS
北大核心
2011年第2期110-112,共3页
Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词
脑梗死
激肽释放酶类
基质金属蛋白酶9
脑缺血
预后
brain infarction
kallikreins
matrix metalloproteinase 9
brain ischemia
prognosis
